GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (BUE:PFE) » Definitions » Cyclically Adjusted PS Ratio

Pfizer (BUE:PFE) Cyclically Adjusted PS Ratio : 2.61 (As of May. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Pfizer Cyclically Adjusted PS Ratio?

As of today (2024-05-21), Pfizer's current share price is ARS8113.50. Pfizer's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ARS3,111.51. Pfizer's Cyclically Adjusted PS Ratio for today is 2.61.

The historical rank and industry rank for Pfizer's Cyclically Adjusted PS Ratio or its related term are showing as below:

BUE:PFE' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.22   Med: 4.04   Max: 6.59
Current: 2.49

During the past years, Pfizer's highest Cyclically Adjusted PS Ratio was 6.59. The lowest was 2.22. And the median was 4.04.

BUE:PFE's Cyclically Adjusted PS Ratio is ranked worse than
55.65% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.135 vs BUE:PFE: 2.49

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pfizer's adjusted revenue per share data for the three months ended in Mar. 2024 was ARS4,400.462. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ARS3,111.51 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pfizer Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Pfizer's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Cyclically Adjusted PS Ratio Chart

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.41 4.43 6.29 4.74 2.57

Pfizer Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.68 3.28 2.94 2.57 2.42

Competitive Comparison of Pfizer's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted PS Ratio falls into.



Pfizer Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Pfizer's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=8113.50/3111.51
=2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Pfizer's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4400.462/131.7762*131.7762
=4,400.462

Current CPI (Mar. 2024) = 131.7762.

Pfizer Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 32.210 100.560 42.209
201409 32.506 100.428 42.653
201412 35.202 99.070 46.823
201503 30.457 99.621 40.288
201506 34.503 100.684 45.158
201509 36.407 100.392 47.789
201512 58.170 99.792 76.814
201603 61.020 100.470 80.033
201606 59.779 101.688 77.467
201609 63.281 101.861 81.866
201612 70.705 101.863 91.469
201703 64.680 102.862 82.861
201706 70.442 103.349 89.818
201709 76.394 104.136 96.671
201712 86.342 104.011 109.390
201803 85.865 105.290 107.465
201806 112.850 106.317 139.874
201809 163.499 106.507 202.290
201812 14.728 105.998 18.310
201903 178.359 107.251 219.146
201906 208.964 108.070 254.803
201909 251.068 108.329 305.409
201912 39.134 108.420 47.564
202003 222.998 108.902 269.839
202006 240.359 108.767 291.205
202009 270.891 109.815 325.065
202012 328.481 109.897 393.878
202103 461.887 111.754 544.638
202106 630.610 114.631 724.927
202109 821.010 115.734 934.810
202112 834.743 117.630 935.133
202203 957.025 121.301 1,039.671
202206 1,168.836 125.017 1,232.033
202209 1,100.227 125.227 1,157.772
202212 1,417.657 125.222 1,491.860
202303 1,275.262 127.348 1,319.608
202306 1,069.897 128.729 1,095.226
202309 1,640.290 129.860 1,664.500
202312 1,822.136 129.419 1,855.318
202403 4,400.462 131.776 4,400.462

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pfizer  (BUE:PFE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Pfizer Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Pfizer's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer (BUE:PFE) Business Description

Industry
Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer (BUE:PFE) Headlines

From GuruFocus

Pfizer Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc's Dividend Analysis

By GuruFocus Research 01-24-2024

Pfizer Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc at Truist BioPharma Symposium Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc to Discuss Climate Action Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Pfizer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc to Review Oral GLP-1 Data Call Transcript

By GuruFocus Research 01-23-2024